Member Info for Brand

Slide 18 of the AMR deck. This seems like it's a big deal.

Good little article here on those early years at SNG Towers

https://issuu.com/university_of_southampton/docs/reaction_magazine_summer_2022/s/16390083

Live feed here - https://youtu.be/0i26aOKo1Mc

As per the NYT

"Coming up with successful new innovations, he said, will take time. But Steve Brozak, an investment banker whose company, WBB Securities, specializes in biotechnology, said that if the agency were going to be a success, Dr. Wegrzyn would have to move quickly to distinguish its work from the rest of the federal bureaucracy.

“What she needs to do is get a win on the board right away,” he said. “That does not mean money. That means something that can be identifiable in advancing health care for all, outside of the current paradigm.”

https://www-nytimes-com.cdn.ampproject.org/v/s/www.nytimes.com/2022/09/12/us/politics/biden-cancer-arpa-h.amp.html?amp_gsa=1&_js_v=a9&usqp=mq331AQIKAGwASCAAgM%3D#amp_tf=From%20%251%24s&aoh=16630671556255&csi=0&referrer=https%3A%2F%2Fwww.google.com&share=https%3A%2F%2Fwww.nytimes.com%2F2022%2F09%2F12%2Fus%2Fpolitics%2Fbiden-cancer-arpa-h.html

https://www.whitehouse.gov/briefing-room/statements-releases/2022/09/12/president-biden-announces-intent-to-appoint-dr-renee-wegrzyn-as-inaugural-director-of-advanced-research-projects-agency-for-health-arpa-h/

Today, President Joe Biden announced his intent to appoint Dr. Renee Wegrzyn as the first director of the Advanced Research Projects Agency for Health (ARPA-H), a new agency established to drive biomedical innovation that supports the health of all Americans.

"On Wednesday, the White House will host a summit on the bioeconomy and biomanufacturing. We will announce new investments and resources across a wide range of agencies that will allow the United States to harness the full potential of biotechnology and biomanufacturing."

https://www.whitehouse.gov/briefing-room/press-briefings/2022/09/12/background-press-call-on-president-bidens-executive-order-to-launch-a-national-biotechnology-and-biomanufacturing-initiative/

Biden has bypassed Congress with this Executive Order, which tells (amongst other things) US govt procurement to increase their spend on biotech.

There may still be a covid bill in Congress if the WH is after +++ billions for Vax or treatments, but this whole doc is now law and money will be spent.

"
Within 180 days of the date of this order and annually thereafter, procuring agencies shall report previous fiscal year spending to the Director of OMB on the following:

(i) the number and dollar value of contracts entered into during the previous fiscal year that include the direct procurement of biobased products;

(ii) the number of service and construction (including renovations) contracts entered into during the previous fiscal year that include language on the use of biobased products; and

(iii) the types and dollar values of biobased products actually used by contractors in carrying out service and construction (including renovations) contracts during the previous fiscal year.

(d) The requirements in subsection (c) of this section shall not apply to purchase card transactions and other “[a]ctions not reported” to the Federal Procurement Data System pursuant to 48 CFR 4.606(c).

(e) Within 1 year of the date of this order and annually thereafter, the Director of OMB shall publish information on biobased procurement resulting from the data collected under subsection (c) of this section and information reported under 7 U.S.C. 8102, along with other related information, and shall use scorecards or similar systems to encourage increased biobased purchasing"

Sec. 9. Reducing Risk by Advancing Biosafety and Biosecurity. (a) The United States Government shall launch a Biosafety and Biosecurity Innovation Initiative, which shall seek to reduce biological risks associated with advances in biotechnology, biomanufacturing, and the bioeconomy. Through the Biosafety and Biosecurity Innovation Initiative — which shall be established by the Secretary of HHS, in coordination with the heads of other relevant agencies as determined by the Secretary — agencies that fund, conduct, or sponsor life sciences research shall implement the following actions, as appropriate and consistent with applicable law:

(i) support, as a priority, investments in applied biosafety research and innovations in biosecurity to reduce biological risk throughout the biotechnology R&D and biomanufacturing lifecycles; and

(ii) use Federal investments in biotechnology and biomanufacturing to incentivize and enhance biosafety and biosecurity practices and best practices throughout the United States and international research enterprises.

This seems pretty good you guys

https://www.whitehouse.gov/briefing-room/presidential-actions/2022/09/12/executive-order-on-advancing-biotechnology-and-biomanufacturing-innovation-for-a-sustainable-safe-and-secure-american-bioeconomy/

I googled it so you don't have to ;-)

"Translational research (also called translation research, translational science, or, when the context is clear, simply translation)[1][2] is research aimed at translating (converting) results in basic research into results that directly benefit humans. The term is used in science and technology, especially in biology and medical science. As such, translational research forms a subset of applied research."

https://www.science.org/doi/10.1126/sciimmunol.add4906

"These data also have translational potential because they identify pDCs and the IFN-I pathway as potential therapeutic targets for critically ill patients with COVID-19."

Have a look through the AMR conference attendees, delegates, speakers etc. They are all there and so is RM.

The CEO is literally in DC with reps of BARDA, NIH etc right now.

What a shower lol

I am certainly open to that POV. But it's also been published overnight, from the uni of Southampton, doesn't exist anywhere else on the web. SSH is chairing a allergy symposium this week.

Patagucci - fully agreed. The approach to Comms from the company (in the face of relentless criticism from short term investors) means when they publish something w the word positive, it's exceptionally credible.

This is of course not an RNS but an interview with SSH

Pretty exciting this news dropping while RM (and presumably team) are in DC

That one Def stood out for me Wigster ;-)

Published overnight - couple of solid quotes in there :)

https://www.imperial.ac.uk/be-inspired/magazine/issue-52/a-working-life/